Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes  
Phillip Home Send to Friends Free Subscription Give Comments 中文版
11 Sep, 2024 (Wednesday)



SKB BIO(6990)
Analysis:
Sichuan Kelun-Biotech Biopharmaceutical (06990) is a biopharmaceutical company committed to the research and development (R&D), manufacturing and commercialization of novel drugs in oncology, immunology and other therapeutic areas. We have two antibody drug conjugate (ADC) drugs as our Core Products, namely, sac-TMT and A166. Sac-TMT is a novel NDA-stage TROP2 ADC positioned as a monotherapy and part of combination therapies for treating various advanced solid tumors. A166 is a differentiated NDA-stage HER2 ADC positioned as a monotherapy to treat advanced HER2-positive (HER2+) solid tumors. The company`s revenue for the six months ended June 30, 2024 was RMB1,382.79 million, representing an increase of 32.2% YoY. The increase was mainly attributable to our reinforced collaboration with MSD and receipt of a total of US$90.0 million in milestone payments for the first half of 2024. Profit for the reporting period turned from a loss of RMB31.13 million in the same period last year to a profit of RMB310.23 million. In the second half of 2024, main goal is to advance our pipeline of over 10 clinical-stage drug candidates. The company expect to submit IND applications for multiple pre-clinical assets, promote the joint management of projects under collaboration with the partners and receive further milestone payments.
Strategy:
Buy-in Price: $173.50, Target Price: $192.50, Cut Loss Price: $157.00



Report Review of August 2024

Sectors:

TMT, Semiconductors, Consumer & Healthcare (Eric Li)

TMT, Semiconductors, Consumer & Healthcare (Eric Li)

This month I released reports of 361 DEGREES INT. (1361.HK).

During 2023FY, 361 Degrees International Limited (361 Degrees) recorded a revenue of RMB8,423.3mn, increasing 21.0% YoY. Profit attributable to the equity shareholders of the Company was RMB961mn, representing a YoY increase of 28.7%. A total dividend of HK20.4 cents per ordinary share (equivalent to RMB18.7 cents), representing a dividend payout ratio of 40.2%.

In terms of product segment, sales of the company's two core product lines, namely footwear and apparel, increased by 23.0% YoY and 9.8% YoY respectively. For the year under review, the proportions of total revenue of footwear and apparel sales were slightly increased from 41.0% to 41.7% YoY and slightly decreased from 35.2% to 31.9% YoY of the total revenue respectively. This was mainly due to the increase in proportion of sales revenue from 361 Degrees Kids from 20.7% to 23.2% of the total revenue for the year under review, which in turn affected the proportion of sales of various products to total revenue. The average wholesale price (AWP) of footwear and apparel edged up by 3.0% and 0.5% year-on-year respectively. The increase in footwear's and apparel's AWP was mainly due to the upward adjustments of the wholesale prices of the existing products across different product lines in order to cover the increase in cost of production and reflect the continuous brand image enhancement; the upgrade of product mix by launching a variety of new products with a higher AWP; and the increase in proportion of sales revenue generated from the e-commerce business which has a higher AWP than the sales made to distributors, above reasons contributed to increase in AWP as compared to that of last year. In addition, the sales volume of footwear and apparel products increased by 19.4% and 9.4% YoY, respectively.

In recent years, as China's consumer preferences leaned towards specialisation, diversification, and cost effectiveness, the company positions as a "professional, youthful, and internationalised" brand. The company has built a diversified brand matrix based on professional functions and its own-branded IP. With 2024 bringing numerous international and domestic sports events, including the highly anticipated Paris Olympics, which are expected to stimulate a broader participation in sports and increase consumer demand. We expect 2024-2025 EPS to be RMB0.49 and RMB0.53 respectively, with PT of HKD4.02, implies a FY2024E P/E of 7.47x (~2-yrs historical average). Our investment rating is “Accumulate”.

Click Here for PDF format...




Writer Info
Research Team
Tel: + (852) 2277 6555
Email:
research@phillip.com.hk

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the “Group”) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products’ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

版權所有, 翻印必究。

Copyright(C) 2024 Phillip Securities (HK) Ltd. All Rights Reserved.